Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
LEXX 
Lexaria Bioscience Corp (LEXX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: LEXX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $6
1 Year Target Price $6
| 0 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -15.03% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 15.63M USD | Price to earnings Ratio - | 1Y Target Price 6 |
Price to earnings Ratio - | 1Y Target Price 6 | ||
Volume (30-day avg) 2 | Beta 0.79 | 52 Weeks Range 0.78 - 4.38 | Updated Date 08/15/2025 |
52 Weeks Range 0.78 - 4.38 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.68 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-07-18 | When - | Estimate -0.1567 | Actual -0.21 |
Profitability
Profit Margin - | Operating Margin (TTM) -2155.41% |
Management Effectiveness
Return on Assets (TTM) -84.74% | Return on Equity (TTM) -152.89% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 11119069 | Price to Sales(TTM) 25.37 |
Enterprise Value 11119069 | Price to Sales(TTM) 25.37 | ||
Enterprise Value to Revenue 18.05 | Enterprise Value to EBITDA -7.22 | Shares Outstanding 19559200 | Shares Floating 18111409 |
Shares Outstanding 19559200 | Shares Floating 18111409 | ||
Percent Insiders 7.13 | Percent Institutions 6.3 |
Upturn AI SWOT
Lexaria Bioscience Corp
Company Overview
History and Background
Lexaria Bioscience Corp. was founded to develop and commercialize innovative drug delivery technologies. It focuses on improving the way active pharmaceutical ingredients (APIs) enter the bloodstream, aiming to enhance the effectiveness of various treatments. Its founding year and early milestones are focused on DehydraTECHu2122 technology development.
Core Business Areas
- DehydraTECHu2122 Technology Licensing: Lexaria's core business revolves around licensing its patented DehydraTECHu2122 drug delivery technology to companies in various sectors, including nicotine, cannabidiol (CBD), and pharmaceuticals. This technology aims to improve the oral bioavailability of active ingredients.
- Research and Development: The company invests in research and development to expand the applications of DehydraTECHu2122 technology and conduct clinical trials to validate its efficacy and safety in different therapeutic areas, focusing on hypertension and dementia.
Leadership and Structure
Lexaria is led by a management team with expertise in biotechnology, drug development, and finance. The organizational structure includes departments for research and development, licensing, operations, and administration. Chris Bunka is CEO.
Top Products and Market Share
Key Offerings
- DehydraTECHu2122 Technology: DehydraTECHu2122 is Lexaria's primary offering, a patented drug delivery technology designed to increase the bioavailability of orally administered drugs. Market share is difficult to quantify directly as it's a technology license, not a direct product. Revenue comes from licensing agreements. Competitors include companies offering alternative drug delivery systems, such as nanoemulsions and liposomes.
Market Dynamics
Industry Overview
The pharmaceutical and nutraceutical industries are increasingly focused on improving drug delivery methods to enhance efficacy, reduce side effects, and increase patient compliance. There's a growing demand for technologies that can improve the bioavailability and absorption of orally administered drugs.
Positioning
Lexaria positions itself as a leader in drug delivery technology, focusing on its DehydraTECHu2122 platform. Its competitive advantage lies in its patented technology, which has shown promise in improving drug absorption and onset of action. They are focused on blood pressure management and dementia studies.
Total Addressable Market (TAM)
The TAM for drug delivery technologies is substantial, estimated to be in the billions of dollars globally. Lexaria is positioned to capture a portion of this market through licensing agreements and partnerships, focusing on specific applications like hypertension and dementia.
Upturn SWOT Analysis
Strengths
- Patented DehydraTECHu2122 technology
- Potential for improved drug bioavailability
- Focus on clinical validation
- Multiple potential applications (nicotine, CBD, pharmaceuticals)
- Management team expertise
Weaknesses
- Limited revenue generation to date
- Reliance on licensing agreements
- Requires further clinical validation
- High R&D expenses
- Small company size
Opportunities
- Expansion of licensing agreements
- Successful clinical trial results
- Partnerships with major pharmaceutical companies
- Development of new DehydraTECHu2122 applications
- Growing demand for improved drug delivery technologies
Threats
- Competition from other drug delivery technologies
- Regulatory hurdles
- Failure to secure licensing agreements
- Unsuccessful clinical trials
- Patent infringement
Competitors and Market Share
Key Competitors
- NVCN
- GNRS
- ABBV
Competitive Landscape
Lexaria's competitive advantage lies in its patented DehydraTECHu2122 technology. However, it faces competition from larger pharmaceutical and biotechnology companies with greater resources and established market presence.
Growth Trajectory and Initiatives
Historical Growth: Lexaria's growth has been primarily driven by technology development and securing initial licensing agreements. Revenue generation has been limited.
Future Projections: Future growth depends on the success of clinical trials, expansion of licensing agreements, and potential partnerships with pharmaceutical companies. Analyst estimates are not uniformly available.
Recent Initiatives: Recent initiatives include ongoing clinical trials for DehydraTECHu2122 in hypertension and dementia, as well as pursuing new licensing opportunities.
Summary
Lexaria Bioscience Corp. is a high-risk, high-reward development-stage company with a patented drug delivery technology. Its success hinges on the results of ongoing clinical trials and the ability to secure licensing agreements. The company's limited revenue and reliance on R&D funding pose significant challenges. Successful clinical outcomes and partnerships are crucial for future growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Lexaria Bioscience Corp. website
- SEDAR+
- Third party market data
Disclaimers:
This analysis is based on publicly available information and should not be considered financial advice. Market share estimates are approximate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Lexaria Bioscience Corp
Exchange NASDAQ | Headquaters Kelowna, BC, Canada | ||
IPO Launch date 2006-10-10 | CEO & Director Mr. Richard C. Christopher | ||
Sector Healthcare | Industry Biotechnology | Full time employees 7 | Website https://lexariabioscience.com |
Full time employees 7 | Website https://lexariabioscience.com | ||
Lexaria Bioscience Corp. operates as a biotechnology company. It offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules, including glucagon-like peptide-1 drugs (GLP-1) and glucose -dependent insulinotropic polypeptide drugs (GIP), vitamins, pain medications, hormones, phosphodiesterase type 5 (PDE5) inhibitors, antivirals, nicotine and its analogs, and cannabinoids. Its DehydraTECH technology is applied to various therapeutic indications, such as diabetes, weight loss, hypertension, and heart disease; is implemented in a multitude of ingestible or topically administered product formats comprising oral suspensions, tablets, capsules, foods, beverages, creams, lotions, and skin patches; and is suitable for a variety of product formats, including pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The company was formerly known as Lexaria Corp. and changed its name to Lexaria Bioscience Corp. in April 2016. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.